Matthew Gitlin
Amgen
66 Papers
221 Citations
Matthew Gitlin is an academic researcher from Amgen. The author has contributed to research in topics: Medicine & Population. The author has an hindex of 16, co-authored 51 publications.
Chat about Author
Papers
Epidemiology and Costs of Sepsis in the United States—An Analysis Based on Timing of Diagnosis and Severity Level*
TL;DR: The highest burden of incidence and total costs occurred in the lowest severity sepsis cohort population, and those with increasing severity had a higher economic burden and mortality on a case-by-case basis.
605
Economic Evaluation of Chimeric Antigen Receptor T-Cell Therapy by Site of Care Among Patients With Relapsed or Refractory Large B-Cell Lymphoma.
Gary H. Lyman,Gary H. Lyman,Andy Nguyen,Sophie Snyder,Matthew Gitlin,Karen C. Chung +5 more
- 01 Apr 2020
TL;DR: The administration of chimeric antigen receptor T-cell therapy in the outpatient setting of nonacademic specialty oncology networks was associated with lower estimated overall costs.
Systematic review of the impact of erythropoiesis-stimulating agents on fatigue in dialysis patients
Kirsten L. Johansen,Fredric O. Finkelstein,Dennis A. Revicki,Christopher J. Evans,Shaowei Wan,Matthew Gitlin,Irene Agodoa +6 more
TL;DR: Partial correction of anemia with ESA results in improvement of fatigue among patients on dialysis, most strikingly in those patients with baseline Hb levels <10 g/dL.
94
An update on the impact of pre-transplant transfusions and allosensitization on time to renal transplant and on allograft survival
Juan C. Scornik,Jonathan S. Bromberg,Douglas J. Norman,Mayank Bhanderi,Matthew Gitlin,Jeffrey Petersen +5 more
TL;DR: It is indicated that avoiding transfusions whenever possible is a sound management option that could prevent detrimental effects in patients awaiting kidney transplantation.
Increased healthcare costs by later stage cancer diagnosis
TL;DR: In this article , a retrospective analysis was conducted using Optum's de-identified Integrated Claims-Clinical data set with Enriched Oncology, which includes data from Medicare Advantage and commercially insured members.